Similar articles for PMID: 20075367

Year	Number of Results
2004	3
2005	1
2006	1
2007	3
2008	3
2009	10
2010	12
2011	7
2012	11
2013	9
2014	10
2015	5
2016	6
2017	6
2018	2
2019	5
2020	1
2024	0

1

Randomized clinical trials with biomarkers: design issues.

Freidlin B, McShane LM, Korn EL. Freidlin B, et al. J Natl Cancer Inst. 2010 Feb 3;102(3):152-60. doi: 10.1093/jnci/djp477. Epub 2010 Jan 14. J Natl Cancer Inst. 2010. PMID: 20075367 Free PMC article.

2

Midostaurin in FLT3-mutated acute myeloid leukaemia.

Das M. Das M. Lancet Oncol. 2017 Aug;18(8):e439. doi: 10.1016/S1470-2045(17)30506-5. Epub 2017 Jun 29. Lancet Oncol. 2017. PMID: 28669736 No abstract available.

3

Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison.

Qi WX, Tang LN, He AN, Shen Z, Lin F, Yao Y. Qi WX, et al. Curr Med Res Opin. 2012 Apr;28(4):643-50. doi: 10.1185/03007995.2012.675880. Epub 2012 Mar 29. Curr Med Res Opin. 2012. PMID: 22414178 Review.

4

Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature.

Tassinari D, Carloni F, Santelmo C, Tamburini E, Lazzari Agli L, Tombesi P, Sartori S. Tassinari D, et al. Rev Recent Clin Trials. 2009 Jan;4(1):27-33. doi: 10.2174/157488709787047549. Rev Recent Clin Trials. 2009. PMID: 19149760 Review.

5

Lung cancer trials probe effects of maintenance therapy, targeted agents.

Hampton T. Hampton T. JAMA. 2009 Aug 12;302(6):616, 618. doi: 10.1001/jama.2009.1118. JAMA. 2009. PMID: 19671897 No abstract available.

6

Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.

[No authors listed] [No authors listed] Clin Lung Cancer. 2004 May;5(6):337-9. doi: 10.1016/s1525-7304(11)70184-x. Clin Lung Cancer. 2004. PMID: 15217532 Review. No abstract available.

7

The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.

Gridelli C, Maione P, Rossi A. Gridelli C, et al. Rev Recent Clin Trials. 2013 Mar;8(1):23-8. doi: 10.2174/15748871112079990040. Rev Recent Clin Trials. 2013. PMID: 23259416

8

Clairvoyance or reliable prediction of the future?

van Zandwijk N, van de Vijver MJ. van Zandwijk N, et al. Ann Oncol. 2007 Mar;18(3):407-8. doi: 10.1093/annonc/mdl503. Ann Oncol. 2007. PMID: 17322538 Free article. No abstract available.

9

Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.

Li T, Lara PN Jr, Mack PC, Perez-Soler R, Gandara DR. Li T, et al. Curr Drug Targets. 2010 Jan;11(1):85-94. doi: 10.2174/138945010790030983. Curr Drug Targets. 2010. PMID: 19839922 Review.

10

A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.

Li N, Ou W, Yang H, Liu QW, Zhang SL, Wang BX, Wang SY. Li N, et al. Cancer. 2014 May 1;120(9):1379-86. doi: 10.1002/cncr.28591. Epub 2014 Jan 30. Cancer. 2014. PMID: 24481719 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

88 results

Results by year